Cognitive behaviour therapy reduces long term risk of relapse in recurrent major depressive disorder


Q Does adding cognitive behaviour therapy to pharmacotherapy reduce the long term risk of relapse of recurrent major depressive disorder?

CONCLUSIONS

Adding CBT to pharmacotherapy can reduce the risk of relapse of recurrent major depressive disorder over a 6 year period.

Commentary

The prognosis for major depressive disorder (MDD) suggests an illness course that averages four lifetime episodes of 20 weeks duration each, along with a 16% risk for relapse or recurrence associated with each successive episode. Routine antidepressant management of MDD targets symptom reduction within the acute episode as its primary goal, and recommends maintenance treatment for prophylaxis. The report by Fava et al suggests that non-pharmacological prevention in MDD is feasible, something that is of wide interest in light of the high rates of drug default, possibly related to a pharmacological tolerance or discontinuation by patients once they begin to feel better. What is innovative about this work is that a preventive intervention is sequenced with pharmacotherapy induced remission, thereby affording a greater number of people protection against relapse/recurrence at just that point when they might be tempted to stop treatment.

Forty five people with MDD were treated to remission with either a tricylic antidepressant or a selective serotonin reuptake inhibitor over a period of 3–5 months. They were then tapered off their medication and received either CBT (with a lifestyle modification/wellbeing focus) or clinical management. The results of a 6 year follow up indicated a significant difference in the percentage of patients who relapsed (CBT = 8/20; clinical management = 18/20) and in the number of multiple recurrences (CBT = 12; clinical management = 34). The authors ascribe the protective effects of CBT to the targeting of residual anxious or irritable symptoms, often the prodromal signs of a relapse. However, it would be important to distinguish which component of CBT (automatic thoughts/lifestyle modification/wellbeing focus) played the most active role in preventing relapses. While these data nicely complement those from Frank et al’s seminal study of psychotherapeutic prophylaxis following medication withdrawal, some caveats do bear mentioning. This paper is one of a series of publications from this group and as yet, there is no replication of this work at an independent site. At present the impetus for alternatives to maintenance pharmacotherapy is strongest on the patient side. Yet, it is unlikely that practice patterns would change in the absence of information on the effect sizes of CBT wellbeing based prevention compared with antidepressant continuation. At best, we have a compelling notion with some strong preliminary data. This additional information would make it easier to consider medication withdrawal and psychological prophylaxis as a defensible deviation from orthodoxy.

Zindel V Segal, PhD, CPsych
Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Canada
Lucio Bizzini, PhD, Guido Bondolfi, MD, PD
University Hospitals of Geneva, Department of Psychiatry, Geneva, Switzerland

Cognitive behaviour therapy reduces long term risk of relapse in recurrent major depressive disorder

*Evid Based Mental Health* 2005 8: 38
doi: 10.1136/ebmh.8.2.38

Updated information and services can be found at:
http://ebmh.bmj.com/content/8/2/38

These include:

**References**
This article cites 4 articles, 0 of which you can access for free at:
http://ebmh.bmj.com/content/8/2/38#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Depressive disorder (570)
- Neurology (1070)
- Substance dependence (407)
- Cagnitive behavioural psychotherapy (54)
- Clinical trials (epidemiology) (989)
- Epidemiology (1570)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/